COVID-19 nursing: interventions, assessment, and NCLEX review

COVID-19 is caused by SARS-CoV-2, an airborne respiratory virus that can progress from mild upper respiratory illness to life-threatening ARDS, septic shock, and multi-organ failure. Nurses must recognize WHO severity classifications, initiate the correct precautions immediately, manage evolving respiratory failure, administer antivirals and immunomodulators within narrow treatment windows, and prevent complications including VTE, cytokine storm, and secondary infection. This reference consolidates the clinical knowledge needed for bedside management and NCLEX preparation.

COVID-19 at a glance

Pathophysiology

SARS-CoV-2 and ACE2 receptor binding

SARS-CoV-2 infects human cells via its spike (S) protein, which binds to angiotensin-converting enzyme 2 (ACE2) receptors on the surface of type II pneumocytes in the lower respiratory tract, as well as on cells in the intestine, kidney, heart, and vascular endothelium. ACE2 is highly expressed in the alveolar epithelium, which explains why severe pulmonary disease is the hallmark of COVID-19.

After ACE2 binding, the viral spike protein is cleaved by a host serine protease (TMPRSS2), enabling membrane fusion and viral RNA entry into the cell. SARS-CoV-2 replicates rapidly and suppresses the early interferon response – blunting the innate immune alarm system and allowing viral load to peak before the adaptive immune system is fully activated.

Alveolar injury and hypoxemia

Direct viral cytopathic effect destroys type II pneumocytes responsible for surfactant production. Loss of surfactant reduces alveolar surface tension and promotes collapse (atelectasis). Simultaneously, inflammatory exudate floods the alveolar space, creating the bilateral ground-glass opacities seen on CT imaging. Gas exchange is impaired when alveoli are fluid-filled but still perfused – this ventilation-perfusion (V/Q) mismatch is the primary driver of hypoxemia in COVID-19.

Cytokine storm

In a subset of patients, viral invasion triggers an exaggerated, dysregulated inflammatory response. Macrophages and T lymphocytes release massive quantities of pro-inflammatory cytokines – including IL-6, IL-1β, IL-18, and TNF-α – creating a self-amplifying feedback loop. This cytokine storm causes systemic inflammation, endothelial activation, coagulopathy, and multi-organ dysfunction that extends far beyond the lungs. The cytokine storm phase typically occurs in the second week of illness, when respiratory status deteriorates despite decreasing viral load.

Coagulopathy and VTE

SARS-CoV-2 infects vascular endothelial cells directly and also activates endothelium through cytokine-mediated signaling. Endothelial injury triggers platelet aggregation, increased thrombin generation, and impaired fibrinolysis – creating a hypercoagulable state. Elevated D-dimer, fibrinogen, and factor VIII levels are characteristic findings. COVID-19–associated coagulopathy is responsible for the high rates of deep vein thrombosis, pulmonary embolism, stroke, and microvascular thrombosis observed in hospitalized and critically ill patients.

Clinical presentation by WHO severity

Atypical presentations to recognize:

• Older adults may present with delirium, falls, or functional decline rather than classic respiratory symptoms
• Immunocompromised patients may lack fever despite significant viral replication
• Silent hypoxemia: some patients have SpO2 60–80% with minimal dyspnea (particularly in early infection) – routine SpO2 monitoring catches this before clinical deterioration

Nursing assessment

Respiratory assessment

Respiratory status is the highest-priority assessment in COVID-19 and must be performed continuously in moderate-to-critical illness.

• SpO2: Target ≥94% on the minimum required supplemental oxygen. An SpO2 below 94% on room air is the threshold that triggers supplemental oxygen initiation and inpatient evaluation. In critically ill patients, target SpO2 92–96% (avoiding hyperoxia, which can worsen outcomes).
• Respiratory rate: RR >22 breaths/min is an early warning sign. RR >30 breaths/min in a COVID-19 patient indicates severe disease and impending respiratory failure.
• Work of breathing: Assess for accessory muscle use (sternocleidomastoid, intercostals), nasal flaring, tripod positioning, and inability to complete full sentences. These are signs of impending fatigue.
• Auscultation: Bilateral crackles, especially bibasilar, indicate fluid accumulation or consolidation. Coarse breath sounds suggest secretion retention.
• ABG values: In moderate-to-severe disease, monitor for hypoxemic respiratory failure (PaO2 <60 mmHg, PaO2/FiO2 <300) and respiratory alkalosis from compensatory hyperventilation. See the ABG interpretation cheat sheet for reference ranges.

Cardiovascular assessment

• Monitor for tachycardia (compensatory response to hypoxemia and fever); sustained HR >100 requires investigation
• Assess BP trends: hypotension in COVID-19 may indicate septic shock, cardiomyopathy, or severe cytokine storm – see septic shock nursing
• Myocarditis and Takotsubo cardiomyopathy are recognized COVID-19 cardiac complications; monitor for chest pain, troponin elevation, and ECG changes
• Monitor for signs of PE: pleuritic chest pain, sudden tachycardia, desaturation – see pulmonary embolism nursing for full assessment

Neurological assessment

• Assess mental status every shift using a validated tool (GCS, CAM-ICU for delirium)
• COVID-19 encephalopathy, stroke, and Guillain-Barré syndrome are documented neurological complications
• Sudden neurological changes in a COVID-19 patient with elevated D-dimer must raise suspicion for embolic stroke

Key laboratory trends

Nursing interventions by severity

Mild disease (outpatient)

• Educate on home isolation: separate sleeping space, dedicated bathroom, mask use with household contacts, hand hygiene
• Instruct patient to monitor SpO2 with home pulse oximeter; return precautions for SpO2 <94%, worsening dyspnea, persistent chest pain, confusion, or inability to stay awake
• Administer nirmatrelvir/ritonavir (Paxlovid) within 5 days of symptom onset to eligible high-risk patients (age ≥50, immunocompromised, unvaccinated, comorbidities) – assess for drug interactions before prescribing; contraindicated with several CYP3A4-sensitive medications
• Ensure adequate hydration; antipyretics (acetaminophen preferred) for fever and myalgia
• Discuss vaccination status and refer for updated vaccine at recovery

Moderate disease (hospital ward)

• Initiate supplemental O2 to maintain SpO2 ≥94%; start with nasal cannula (1–6 L/min), escalate to face mask or Venturi mask as needed
• Position patient in awake prone positioning for 8–12 hours per day: evidence shows improved oxygenation in non-intubated COVID-19 patients. Assess for contraindications (hemodynamic instability, facial trauma, agitation)
• IV remdesivir 200 mg loading dose day 1, then 100 mg daily for up to 5 days (for patients requiring supplemental O2 but not mechanical ventilation)
• Begin dexamethasone 6 mg PO/IV daily only if patient requires supplemental O2 or is on mechanical ventilation; do not start in patients who do not need O2
• Initiate VTE prophylaxis with LMWH (enoxaparin) within 12–24 hours of admission unless contraindicated
• Continuous SpO2 monitoring; notify provider for SpO2 <92% or RR >28 breaths/min
• Monitor daily labs: CBC, CMP, CRP, ferritin, D-dimer, LDH, coagulation panel

Severe disease (high-flow oxygen / NIV)

• High-flow nasal cannula (HFNC): Provides flows up to 60 L/min with heated, humidified O2 and FiO2 up to 100%. HFNC is preferred over standard oxygen before escalating to intubation. Monitor ROX index (SpO2/FiO2 ÷ RR) – ROX <3.85 at 12 hours predicts HFNC failure and need for intubation.
• Non-invasive ventilation (NIV/BiPAP): Consider for hypercapnic respiratory failure; less effective than HFNC for hypoxemic failure. Requires tight mask fit and close monitoring for failure.
• Awake prone positioning continues; coordinate with respiratory therapy
• Baricitinib (JAK inhibitor) or tocilizumab (IL-6 receptor antagonist) may be added for patients with rapidly increasing oxygen needs – monitor for immunosuppression-related adverse effects
• Strict fluid balance monitoring; avoid fluid overload, which worsens pulmonary edema
• Therapeutic anticoagulation may be initiated for patients with confirmed VTE or clinical suspicion pending imaging

Critical disease (ICU / mechanical ventilation)

• Lung-protective ventilation (LPV): Tidal volume 4–8 mL/kg of ideal body weight (NOT actual body weight), plateau pressure ≤30 cmH2O, PEEP titrated to oxygenation and driving pressure. High tidal volumes cause ventilator-induced lung injury (VILI) and must be avoided.
• Prone positioning: Continuous prone positioning for ≥16 hours/day in mechanically ventilated patients with severe ARDS (P/F ratio <150). See ARDS nursing reference for full proning protocol including team roles, contraindications, and monitoring.
• Neuromuscular blockade (cisatracurium) may be used in the first 48 hours of severe ARDS for ventilator dyssynchrony or refractory hypoxemia
• Vasopressors (norepinephrine first line) for septic shock component; target MAP ≥65 mmHg – full vasopressor management in septic shock nursing reference
• Monitor for secondary infections: VAP bundle compliance (HOB 30–45°, oral care, daily sedation vacation, DVT and stress ulcer prophylaxis)
• CRRT or intermittent hemodialysis for AKI with fluid overload or electrolyte emergency
• Regular delirium assessment (CAM-ICU); minimize sedation depth; promote sleep hygiene and reorientation

Medications

Complications

ARDS

Acute respiratory distress syndrome is the most common cause of ICU admission and death in COVID-19. The 2024 Global Definition of ARDS supersedes the 2012 Berlin Definition and is the criteria set to know: acute onset within one week of a known insult, bilateral opacities on chest radiograph, CT, or ultrasound, respiratory failure not fully explained by cardiac failure or fluid overload, and hypoxemia defined by PaO2/FiO2 ≤300 mmHg or SpO2/FiO2 ≤315 when SpO2 is ≤97%. The pulse-oximetry criterion matters directly for COVID-19 nursing, because it lets ARDS be identified without an arterial blood gas.

The single largest change from Berlin is that the Global Definition creates a non-intubated ARDS category: patients on high-flow nasal oxygen at ≥30 L/min who otherwise meet criteria now qualify. Under Berlin these patients were excluded because invasive or non-invasive ventilation was required. A separate resource-limited-setting category drops the PEEP and oxygen-delivery-device requirements. COVID-19 ARDS frequently presents with unusually preserved compliance early in the disease (sometimes called “happy hypoxemia” or L-phenotype ARDS), which makes it distinct from classic ARDS. Full management including P/F ratio calculation, prone positioning, and sedation protocols is covered in the ARDS nursing reference.

Cytokine storm

Cytokine storm typically develops in the second week of illness and is characterized by: persistent fever unresponsive to antipyretics, rapidly escalating oxygen requirements, markedly elevated ferritin (>1,000 ng/mL), elevated IL-6, and evidence of multi-organ injury. It is treated with immunomodulators (dexamethasone, tocilizumab, baricitinib) rather than antivirals. Nursing priorities include early recognition of the inflammatory trajectory and coordinating rapid escalation of therapy.

VTE and pulmonary embolism

COVID-19 carries a VTE rate of 20–30% in ICU patients despite pharmacologic prophylaxis – among the highest of any acute illness. Nurses must maintain vigilance for: sudden desaturation (PE), unilateral leg swelling (DVT), pleuritic chest pain, and tachycardia out of proportion to clinical status. D-dimer elevation is expected in COVID-19, but trends above 3–5 µg/mL warrant imaging. See pulmonary embolism nursing for full assessment and therapeutic anticoagulation management.

Long COVID

Long COVID (post-acute sequelae of SARS-CoV-2, PASC) describes symptoms persisting beyond 12 weeks after acute infection. Common manifestations include: post-exertional malaise, fatigue, brain fog/cognitive impairment, dyspnea on exertion, chest pain, palpitations (POTS – postural orthostatic tachycardia syndrome), anosmia/ageusia, anxiety, and depression. Prevalence estimates depend heavily on whether the question asked is “ever” or “currently.” In the CDC Household Pulse Survey, close to 30% of US adults who have had COVID-19 report having experienced long COVID at some point, while roughly 10% report currently having it in any given month. Long COVID is not predicted by initial illness severity – patients with mild acute disease can develop significant long COVID. Nursing education at discharge should address the possibility of persistent symptoms and the importance of follow-up.

MIS-C and MIS-A

Multisystem inflammatory syndrome in children (MIS-C) and adults (MIS-A) are rare but life-threatening post-COVID hyperinflammatory syndromes. MIS-C occurs in children typically 2–6 weeks after COVID-19 infection and presents with fever, mucocutaneous inflammation (similar to Kawasaki disease), GI symptoms, and cardiac involvement (coronary artery dilation, myocarditis, ventricular dysfunction). MIS-A follows a similar pattern in adults. Treatment includes IV immunoglobulin, steroids, and cardiovascular support.

Secondary infection

Immunosuppression from dexamethasone and tocilizumab increases the risk of secondary bacterial pneumonia, aspergillosis (COVID-19–associated pulmonary aspergillosis, CAPA), and other opportunistic infections. Monitor for rising procalcitonin, new fever spikes after initial defervescence, changing sputum character, or clinical deterioration after initial improvement. These findings require culture-directed antimicrobial therapy and medication review.

Infection control and PPE

CDC’s interim SARS-CoV-2 recommendations now sit in the “Respiratory infectious disease, acute” row of Appendix A to its isolation guideline, which CDC lists as under review. They call for a single-person room and an N95 respirator or higher, gown, gloves and eye protection for all care, with aerosol-generating procedures performed in an AIIR if possible. Many textbooks and NCLEX resources label this “airborne + contact precautions”. The CDC wording differs in one practical way: a negative-pressure room is reserved for aerosol-generating procedures, while the full PPE set applies at every encounter. Either way, the PPE is more stringent than for influenza, which uses droplet precautions with a surgical mask put on at room entry. See influenza nursing reference for a direct comparison.

NCLEX key point: The N95 vs surgical mask distinction is a high-yield topic. COVID-19 → N95 plus gown, gloves and eye protection for all care. Influenza (droplet) → surgical mask (upgrade to N95 for AGPs). TB (airborne) → N95.

Special populations

Immunocompromised patients

Immunocompromised patients (solid organ transplant recipients, hematologic malignancy, biologic therapy, HIV with low CD4 count) are at significantly elevated risk of severe COVID-19, prolonged viral shedding, and drug-resistant variants emerging within a single host. Key nursing considerations:

• Fever may be absent despite severe infection – do not use fever as the sole trigger for isolation
• Moderately to severely immunocompromised patients can shed replication-competent virus beyond 20 days; CDC recommends a test-based strategy to end precautions (two negative respiratory specimens collected 48 hours apart) and infectious disease consultation if available. For patients who are not moderately to severely immunocompromised, the symptom-based rule is at least 10 days after symptom onset for mild to moderate illness (10 to 20 days for severe or critical illness), at least 24 hours since the last fever without fever-reducing medication, and improving symptoms; asymptomatic patients need at least 10 days from the first positive viral test [18]
• Nirmatrelvir/ritonavir drug interactions are extensive in transplant patients on calcineurin inhibitors (cyclosporine, tacrolimus) – dose adjustment or alternative antivirals required
• CAPA (COVID-19–associated pulmonary aspergillosis) is significantly more common in this group – monitor galactomannan, consider antifungal prophylaxis per institutional protocol

Pregnant patients

COVID-19 in pregnancy is associated with increased risks of ICU admission, preterm birth, cesarean delivery, and preeclampsia compared to non-pregnant adults of the same age. Key nursing considerations:

• SpO2 target for pregnant COVID-19 patients: ≥95% (higher than the ≥94% general target, to ensure adequate fetal oxygenation)
• Lateral decubitus positioning (left lateral preferred) rather than supine during awake prone positioning to avoid aortocaval compression
• Dexamethasone for fetal lung maturity (if preterm delivery anticipated) may overlap with COVID-19 steroid therapy – coordinate with obstetrics
• Nirmatrelvir/ritonavir is not recommended in pregnancy (insufficient safety data); remdesivir is the preferred antiviral for hospitalized pregnant patients
• Continuous fetal monitoring for hospitalized patients; involve maternal-fetal medicine (MFM) early

Older adults

Advancing age is the single strongest predictor of COVID-19 severity and death. Key nursing considerations:

• Assess for atypical presentation: delirium, syncope, falls, anorexia, or functional decline without prominent respiratory symptoms
• Frailty assessment using Clinical Frailty Scale or similar tool informs escalation decisions and goals-of-care conversations
• Polypharmacy: check Paxlovid interactions meticulously; older patients often take CYP3A4-sensitive medications (statins, anticoagulants, antiarrhythmics)
• Isolation may cause rapid functional decline – plan early physical and occupational therapy
• Comfort-focused care: discuss goals early in the clinical trajectory; document advance directives and POLST/MOLST forms

NCLEX-style practice questions

Question 1. A nurse is caring for a hospitalized patient with COVID-19 who has an SpO2 of 88% on 4 L/min nasal cannula. The patient is alert, cooperative, and denies dyspnea. Which action should the nurse take first?

A. Document the finding and continue monitoring B. Increase oxygen flow rate to 6 L/min C. Prepare the patient for awake prone positioning D. Notify the provider of the SpO2 reading

Answer: D. SpO2 88% on supplemental oxygen indicates that the current oxygen delivery is inadequate. The nurse must notify the provider first so that orders can be obtained for oxygen escalation and reassessment of the treatment plan. Increasing the flow rate (B) requires a provider order. Awake prone positioning (C) is a nursing intervention that should be ordered and implemented after provider notification and assessment, not as a first independent action in acute deterioration.

Question 2. A provider orders dexamethasone 6 mg IV daily for a patient with COVID-19 who does not require supplemental oxygen. What is the nurse’s most appropriate action?

A. Administer the dose as ordered B. Administer the dose and monitor blood glucose C. Clarify the order with the provider before administering D. Administer with a proton pump inhibitor to prevent GI effects

Answer: C. Dexamethasone is indicated for COVID-19 patients requiring supplemental O2 or mechanical ventilation. In patients who do not require O2, dexamethasone may worsen outcomes by impairing viral clearance. The nurse should clarify whether the order is appropriate given the patient’s current oxygenation status before administering.

Question 3. A nurse is preparing to enter the room of a COVID-19 patient for an oral suctioning procedure. Which PPE is most appropriate?

A. Surgical mask, gown, and gloves B. N95 respirator, gown, and gloves C. N95 respirator, gown, gloves, and eye protection D. Surgical mask, gown, gloves, and eye protection

Answer: C. CDC’s interim guidance calls for an N95 respirator or higher, gown, gloves and eye protection for all care of a patient with COVID-19, and suctioning can generate aerosols, which raises the stakes. A surgical mask (A, D) is not a respirator and does not provide adequate protection against aerosolized SARS-CoV-2; option B leaves the eyes unprotected.

Question 4. A nurse notes that a patient with COVID-19 has a D-dimer of 4.2 µg/mL (reference <0.5 µg/mL), new onset of pleuritic chest pain, and heart rate of 118 bpm. What complication should the nurse suspect, and what is the priority action?

A. Cytokine storm – prepare to administer tocilizumab B. Secondary bacterial pneumonia – obtain sputum culture and notify provider C. Pulmonary embolism – notify the provider and anticipate CT pulmonary angiography orders D. Cardiac tamponade – prepare for pericardiocentesis

Answer: C. The triad of markedly elevated D-dimer, pleuritic chest pain, and tachycardia in a COVID-19 patient is a high-risk presentation for pulmonary embolism. COVID-19 carries a hypercoagulable state and high VTE rates. The nurse should immediately notify the provider and anticipate orders for CT pulmonary angiography (CTPA) and possible therapeutic anticoagulation. Cytokine storm (A) presents with fever, escalating oxygen requirements, and hyperferritinemia, not pleuritic pain. Cardiac tamponade (D) would present with Beck’s triad (hypotension, muffled heart sounds, JVD).

Question 5. A nurse is educating a patient with mild COVID-19 who has been prescribed nirmatrelvir/ritonavir (Paxlovid). Which statement by the patient indicates understanding of the medication?

A. “I should start this medication only if my symptoms get worse after 7 days.” B. “I need to start taking this within 5 days of when my symptoms started.” C. “I can stop taking it once I feel better after 2 or 3 days.” D. “This medication will prevent me from spreading COVID to others.”

Answer: B. Paxlovid must be initiated within 5 days of symptom onset to be effective – this is the most critical pharmacological teaching point. A is incorrect (delayed start loses efficacy). C is incorrect (the full 5-day course must be completed even if symptoms improve, and rebound symptoms after course completion are documented). D is incorrect (Paxlovid reduces disease severity but does not reliably prevent transmission).

Question 6. A nurse is caring for a mechanically ventilated COVID-19 patient with severe ARDS. The ventilator settings show a tidal volume of 10 mL/kg ideal body weight. Which action should the nurse prioritize?

A. Notify the provider that tidal volume exceeds lung-protective targets B. Increase PEEP to improve oxygenation C. Administer neuromuscular blockade immediately D. Reposition the patient to full lateral decubitus

Answer: A. Lung-protective ventilation for ARDS requires tidal volumes of 4–8 mL/kg of ideal body weight. A tidal volume of 10 mL/kg causes ventilator-induced lung injury (VILI) through barotrauma and volutrauma. The nurse should notify the provider immediately so the tidal volume can be reduced to protective levels. Increasing PEEP (B) is a separate parameter adjustment that does not correct a dangerously high tidal volume. Neuromuscular blockade (C) and repositioning (D) are important interventions but are not the priority when a patient is receiving injurious tidal volumes.

Key takeaways

• SpO2 <94% on room air is the threshold for supplemental oxygen and inpatient evaluation – monitor all COVID-19 patients even if they appear comfortable.
• Dexamethasone only if requiring O2 or ventilation – it is harmful in mild disease.
• Paxlovid within 5 days for high-risk outpatients; remdesivir for hospitalized patients on supplemental O2.
• VTE risk is high – pharmacologic prophylaxis (LMWH) is standard for all hospitalized patients; monitor D-dimer trends.
• N95 or higher, gown, gloves and eye protection for all COVID-19 care in a single-person room (CDC interim guidance) – stricter than influenza (droplet, surgical mask on room entry). Perform aerosol-generating procedures in an AIIR if possible.
• Prone positioning improves oxygenation in both awake (moderate) and ventilated (critical) patients – know the protocol and contraindications.
• Cytokine storm peaks in week 2 – recognize the trajectory (rising ferritin, escalating O2 needs, persistent fever) and escalate immunomodulator therapy early.
• Long COVID can follow an infection of any initial severity – close to 30% of US adults who have had COVID-19 report ever experiencing it, around 10% currently. Include in discharge education.
• Special populations require modified targets: SpO2 ≥95% in pregnancy; atypical presentation monitoring in older adults; drug interaction vigilance in immunocompromised patients on transplant medications.

For related clinical content: influenza nursing reference | pneumonia nursing reference | ARDS nursing reference | sepsis nursing reference | pulmonary embolism nursing | nursing lab values cheat sheet | levels of nursing

References

[1] World Health Organization – Clinical Management of COVID-19: Living Guideline, June 2025, WHO, published 15 July 2025 (supersedes the 7th version of 18 August 2023). https://www.who.int/publications/i/item/B09467

[2] National Institutes of Health – COVID-19 Treatment Guidelines, NIH, final update 1 March 2024 (the standalone guidelines site was retired in August 2024; archived in full on NCBI Bookshelf). https://www.ncbi.nlm.nih.gov/books/NBK570371/

[3] RECOVERY Collaborative Group; Horby P, Lim WS, Emberson JR, et al. – Dexamethasone in hospitalized patients with Covid-19, New England Journal of Medicine 2021;384(8):693–704. doi:10.1056/NEJMoa2021436

[4] WHO Solidarity Trial Consortium; Pan H, Peto R, Henao-Restrepo AM, et al. – Repurposed antiviral drugs for Covid-19 – interim WHO Solidarity trial results, New England Journal of Medicine 2021;384(6):497–511. doi:10.1056/NEJMoa2023184

[5] Beigel JH, Tomashek KM, Dodd LE, et al. – Remdesivir for the treatment of Covid-19 – final report, New England Journal of Medicine 2020;383(19):1813–1826. doi:10.1056/NEJMoa2007764

[6] Marconi VC, Ramanan AV, de Bono S, et al. – Efficacy and safety of baricitinib for the treatment of hospitalised adults with Covid-19 (COV-BARRIER): a randomised, double-blind, placebo-controlled phase 3 trial, Lancet Respiratory Medicine 2021;9(12):1407–1418. doi:10.1016/S2213-2600(21)00331-3

[7] REMAP-CAP Investigators; Gordon AC, Mouncey PR, Al-Beidh F, et al. – Interleukin-6 receptor antagonists in critically ill patients with Covid-19, New England Journal of Medicine 2021;384(16):1491–1502. doi:10.1056/NEJMoa2100433

[8] Hammond J, Leister-Tebbe H, Gardner A, et al. – Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19 (EPIC-HR trial), New England Journal of Medicine 2022;386(15):1397–1408. doi:10.1056/NEJMoa2118542

[9] Klok FA, Kruip MJHA, van der Meer NJM, et al. – Incidence of thrombotic complications in critically ill ICU patients with Covid-19, Thrombosis Research 2020;191:145–147. doi:10.1016/j.thromres.2020.04.013

[10] Infectious Diseases Society of America – IDSA Guidelines on the Treatment and Management of Patients with COVID-19, IDSA 2024. https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management/

[11] Centers for Disease Control and Prevention – Infection Control Guidance: SARS-CoV-2, CDC (archived; last updated March 18, 2024, last reviewed June 24, 2024). Accessed October 22, 2026. https://archive.cdc.gov/www_cdc_gov/covid/hcp/infection-control/index.html

[12] Alhazzani W, Evans L, Alshamsi F, et al. – Surviving Sepsis Campaign guidelines on the management of adults with coronavirus disease 2019 (COVID-19) in the ICU, Critical Care Medicine 2021;49(3):e219–e234. doi:10.1097/CCM.0000000000004899

[13] Guérin C, Reignier J, Richard JC, et al. – Prone positioning in severe acute respiratory distress syndrome (PROSEVA trial), New England Journal of Medicine 2013;368(23):2159–2168. doi:10.1056/NEJMoa1214103

[14] Ferner RE, Aronson JK – Chloroquine and hydroxychloroquine in covid-19 (lessons from premature conclusions), BMJ 2020;369:m1432. doi:10.1136/bmj.m1432

[15] Dennis JM, McGovern AP, Vollmer SJ, et al. – Improving survival of critical care patients with coronavirus disease 2019 in England: a national cohort study, Critical Care Medicine 2021;49(2):209–214. doi:10.1097/CCM.0000000000004747

[16] Matthay MA, Arabi Y, Arroliga AC, et al. – A new global definition of acute respiratory distress syndrome, American Journal of Respiratory and Critical Care Medicine 2024;209(1):37–47. doi:10.1164/rccm.202303-0558WS

[17] National Center for Health Statistics – Long COVID: Household Pulse Survey, CDC/NCHS. https://www.cdc.gov/nchs/covid19/pulse/long-covid.htm

[18] Centers for Disease Control and Prevention; Healthcare Infection Control Practices Advisory Committee – 2007 Guideline for Isolation Precautions, Appendix A: type and duration of precautions recommended for selected infections and conditions (“Respiratory infectious disease, acute” row, interim SARS-CoV-2 recommendations), CDC, updated September 11, 2026. Accessed October 20, 2026. https://www.cdc.gov/infection-control/hcp/isolation-precautions/appendix-a-type-duration.html